Huons
Huons is a South Korean KOSDAQ-listed pharmaceutical manufacturer producing prescription drugs, OTC brands, medical devices, and biopharmaceutical CDMO services for patients, hospitals, and global pharma clients across Korea, the US, Japan, and China.
- Company typePublic
- Founded1965
- HeadquartersSeongnam, South Korea
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Huons does
Huons is a KOSDAQ-listed South Korean pharmaceutical company headquartered in Seongnam (Gyeonggi Province), operating as the core operating subsidiary of Huons Global following a 2016 holding company restructuring. Founded in 1965 as Gwangmyeong Pharmaceutical Industry, the company runs two GMP-compliant manufacturing facilities in Jecheon Bio Valley for sterile injectables, ophthalmic, and oral formulations, plus the Huons Dongam R&D Center in Gwacheon (completed November 2024). Through its subsidiary network, Huons spans prescription pharmaceuticals (diabetes, cardiovascular, anesthesia/pain, dermatology), OTC products (Nizoral antifungal, Menolacto probiotic), medical devices (DIA:CONN P8 Bluetooth smart insulin pen, Dermashine Duo RF aesthetic device, Elravie dermal fillers, Premium 9Pin Needle), biopharmaceutical CDMO via the December 2024 PanGen Biotech acquisition, and vaccine distribution via a 2026 Sanofi Korea partnership.
The product portfolio rests on proprietary technology including Korea's first plastic container syringe (Patent No. 0381404, 1998), a nano-composite ophthalmic solution patented across Japan, six European countries, Russia, and Saudi Arabia, and the peptide-based HUC1-394 dry eye candidate licensed from Novacell Technology, which received Phase 2 IND approval in March 2026. FDA approvals cover lidocaine (1% and 2%) and saline injections, enabling US exports, though a June 2026 FDA warning letter for smoke study deficiencies and prior Q1 2026 export detention have created regulatory headwinds.
Huons earns revenue through prescription drug sales via hospital, pharmacy, and CSO networks (largely under Korean National Health Insurance reimbursement), direct-to-consumer online sales through huonsmall.com and Naver Brand Stores for non-reimbursed devices like DIA:CONN P8, international exports through Huons USA/Japan and regional distributors, contract manufacturing, and the new Sanofi vaccine distribution channel. Q1 2026 consolidated revenue was KRW 141.9 billion (~USD 94.9 million), down 2.7% YoY, with an operating loss of KRW 649 million driven by US recall warranty costs (KRW 1.07 billion), FDA export detention, and softer contract manufacturing demand.
Huons firmographics
Firmographics- Name
- Huons
- Legal name
- (주)휴온스
- Website
- https://huons.com
- Company type
- Public
- Founded year
- 1965
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Huons is a South Korean KOSDAQ-listed pharmaceutical manufacturer producing prescription drugs, OTC brands, medical devices, and biopharmaceutical CDMO services for patients, hospitals, and global pharma clients across Korea, the US, Japan, and China.
- Ownership category
- akta.pro rank
Where Huons is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices4 records
Markets served
Huons business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Products: Revenue from prescription drugs (specialist pharmaceuticals), OTC products, and anesthetic agents sold through pharmaceutical distribution networks, hospitals, and pharmacies. Includes injectable, oral, and topical formulations across therapeutic categories.
- Medical Devices: Revenue from medical devices including smart insulin pens (DIA:CONN P8), aesthetic devices (Dermashine Duo RF, Premium 9Pin Needle), and other medical equipment sold directly and through distributors.
- Vaccine Distribution: Revenue from distribution and co-promotion of five Sanofi vaccines including influenza, hepatitis A, meningococcal, and adult vaccines through Huons' nationwide logistics and sales network in Korea.
- Contract Manufacturing: Revenue from contract manufacturing services for solid oral dosage forms and injectable products for pharmaceutical clients, including FDA-approved manufacturing capabilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | DIA:CONN P8 Smart Insulin Pen - 31% price reduction |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Huons product offering
Product offeringCore offering
Huons manufactures and distributes a diversified portfolio of pharmaceutical products spanning sterile injectables, topical solutions, oral dosage forms, anesthetics, OTC products, and medical devices including the DIA:CONN P8 Bluetooth smart insulin pen and aesthetic devices. The company also operates contract manufacturing services for solid oral and injectable pharmaceutical products, holds exclusive Korean distribution rights for the Nizoral antifungal brand, and distributes Sanofi vaccines through a nationwide Korean logistics network.
Differentiator
Problem solved
Functional benefit
Brands
- Nizoral (니조랄): Antifungal shampoo and topical solution for dandruff, seborrheic dermatitis, and tinea versicolor treatment
- Menolacto (메노락토)
- DIA:CONN P8
- Elravie (엘라비에)
- Alloon (알룬)
- Veraderm (베러덤)
Products and services
- DIA:CONN P8 Smart Insulin Pen Bluetooth-connected smart insulin pen with data tracking for diabetes patients; clinical study showed 11% greater Time In Range compared to traditional insulin pen users
- Nizoral 2% Solution (Ketoconazole) Topical antifungal shampoo and solution for dandruff, seborrheic dermatitis, and tinea versicolor treatment; OTC consumer product used globally for over 30 years
- Dermashine Duo RF Hybrid medical device combining drug delivery with radiofrequency technology for facial aesthetic treatments, marketed through subsidiary Huons Meditech
- Premium 9Pin Needle Aesthetic medical device needle for cosmetic procedures with China NMPA approval
- Lidocaine Injection Products Local anesthetic injectable products including 1% lidocaine 5mL vials, 0.75% bupivacaine HCl, and 2% lidocaine with FDA approvals for US market
- Saline Injection Products Sterile saline injections for medical use with FDA 510K approval for US market
- HUC1-394 Dry Eye Treatment Pipeline peptide-based ophthalmic solution for dry eye disease with novel inflammation-resolution mechanism distinct from conventional suppressive approaches; licensed from Novacell Technology
- Contract Manufacturing Services Contract manufacturing services for solid oral dosage forms and injectable products for pharmaceutical clients, including FDA-approved manufacturing capabilities
- Sanofi Vaccine Distribution Nationwide Korean distribution and co-promotion of five Sanofi vaccines including influenza, hepatitis A, meningococcal, and adult vaccines through Huons' logistics and sales network
- Menolacto Probiotic Supplement Women's menopause probiotic health supplement exceeding 100 billion KRW in cumulative sales
- Hugtoksi Botulinum Toxin Botulinum toxin product registered in Iraq for aesthetic/therapeutic use
- Biopharmaceutical CDMO Services Biopharmaceutical CDMO services leveraging proprietary PANGEN CHO-TECH platform through subsidiary PanGen Biotech, with 41 production cell lines including biosimilars in development for major reference products
Quantifiable outcome
- Users of DIA:CONN P8 smart insulin pen achieved 11% greater Time In Range compared to traditional insulin pen users
- +2 more outcomes
Companies that use Huons
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Huons technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Huons partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- HuonslabcoreHuons Global announced plans to proceed with a merger between its affiliates Huons and Huonslab to secure long-term growth and fund its biotech unit, addressing Huonslab's capital impairment and inability to raise funds independently while leveraging Huons' manufacturing and development capabilities.
- Sanofi KoreacoreHuons signed a distribution and co-promotion agreement with Sanofi Korea to enter the domestic vaccine market starting April 1, 2026. Huons handles nationwide distribution and marketing of five vaccines developed by Sanofi including influenza, hepatitis A, meningococcal, and adult vaccines, leveraging Huons' logistics and sales network to expand vaccine access in Korea.
- Huons Meditech (Subsidiary)coreHuons Meditech, a subsidiary of Huons Group, launched Dermashine Duo RF hybrid medical device combining drug delivery with radiofrequency technology for facial aesthetic treatments.
- PanGen Biotech (Subsidiary)corePanGen Biotech, a subsidiary of Huons Group acquired in December 2024, leverages its proprietary PANGEN CHO-TECH platform for biopharmaceutical CDMO services, holding 41 production cell lines including biosimilars in development for BMS' Yervoy, J&J's Tremfya, and Amgen's Evenity.
- Novacell TechnologycoreHuons entered a technology licensing agreement with Novacell Technology for the dry eye treatment candidate HUC1-394, a peptide-based ophthalmic solution. Huons received Phase 1 IND approval in January 2024 and Phase 2 IND approval in March 2026 for clinical trials.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Huons competitors and assessment
Company assessmentDirect peers
- Hanmi Pharmaceutical: KOSDAQ-listed Korean pharmaceutical company with a similarly diversified portfolio across prescription drugs, OTC, specialty injectables, and medical devices. Comparable in size, manufacturing footprint, and channel strategy via CSO networks and domestic hospital/pharmacy distribution.
- Daewoong Pharmaceutical: Korean pharma manufacturer with overlapping therapeutic categories (anesthesia, dermatology, gastrointestinal) and direct-to-consumer health supplement brands. Both operate FDA-approved facilities and export injectable and finished dosage products.
- Yuhan Corporation: Korean pharmaceutical manufacturer with broad prescription and OTC portfolio, FDA-approved manufacturing, and international distribution. Similar scale and channel mix including CSO distribution and direct pharmacy supply.
- SK Bioscience: Korean vaccine and biopharmaceutical manufacturer. Directly comparable now that Huons has entered the domestic vaccine market via Sanofi Korea distribution, leveraging overlapping customers and regulatory expertise.
- Bukwang Pharmaceutical: Mid-sized Korean pharmaceutical company with a comparable focus on specialty prescription drugs and CNS/dermatology categories. Operates similar hospital- and pharmacy-channel distribution via CSO networks in Korea.
- Embecta (Becton Dickinson spin-off): Pure-play insulin pen and injection device manufacturer. Directly comparable to Huons' DIA:CONN P8 smart insulin pen business as a global competitor in connected diabetes delivery devices.
Broad incumbents
- Celltrion: Larger Korean biopharma with a major biosimilar franchise. Comparable through PanGen Biotech's biosimilar CDMO platform and the broader Huons Group's biologics ambitions via Huonslab and PanGen.
- LG Chem Life Sciences: Diversified Korean chemical/pharmaceutical company with prescription drugs, vaccines, and biologics. Comparable as a domestic competitor across injectables, ophthalmology, and CDMO adjacencies.
- Novo Nordisk: Global leader in insulin pens (NovoPen) and GLP-1 therapies. Sets the competitive benchmark for DIA:CONN P8 in connected insulin delivery and for Huons' broader diabetes portfolio.
Others
- Huons Global (parent): Holding company and direct parent of Huons. Listed on KOSDAQ, captures consolidated value of Huons plus subsidiaries (Humedix, Huons BioPharma, PanGen, Huons Meditech, Huonslab). Relevant for understanding group-level financials and the pending Huons/Huonslab merger.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Huons social profiles
Digital presenceHuons financial estimates
Financial estimateRevenue estimate
Valuation estimate
Huons leadership team
Management profileNumber of profiles
Profiles2 records
Huons subsidiaries and ownership
Company hierarchySubsidiaries12 records
Huons funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Huons M&A and investment
M&A and investmentM&A1 record
Investments12 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Huons
What does Huons do?
Huons manufactures and distributes a diversified portfolio of pharmaceutical products spanning sterile injectables, topical solutions, oral dosage forms, anesthetics, OTC products, and medical devices including the DIA:CONN P8 Bluetooth smart insulin pen and aesthetic devices. The company also operates contract manufacturing services for solid oral and injectable pharmaceutical products, holds exclusive Korean distribution rights for the Nizoral antifungal brand, and distributes Sanofi vaccines through a nationwide Korean logistics network.
Is Huons a public or private company?
Huons is a public company. It is classified as public and is currently operating.
When was Huons founded?
Huons was founded in 1965. It employs 501 to 1,000 people.
Where is Huons based?
Huons is headquartered in Seongnam, South Korea, in the Asia region.
How does Huons make money?
Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices, vaccine Distribution and contract Manufacturing.
Who are Huons's main competitors?
Direct peers on record are Hanmi Pharmaceutical, Daewoong Pharmaceutical, Yuhan Corporation, SK Bioscience, Bukwang Pharmaceutical and Embecta (Becton Dickinson spin-off). Broad incumbents are Celltrion, LG Chem Life Sciences and Novo Nordisk. Huons Global (parent) is listed as an others.
Does Huons have an API?
No public API is recorded for Huons.